Lumos Diagnostics announced it has secured two new service agreements with Massachusetts-based women's health company Hologic. Hologic is a leading innovator in women's health and has engaged Lumos to conduct two programs of work focused on the further development of a rapid, point-of-care test. The programs covered under these two agreements are expected to be completed by the middle of 2023, and Lumos is entitled to receive up to USD 1.5 million in revenue for the provision of its development services on these programs.
Lumos Diagnostics Holdings Limited
Equities
LDX
AU0000157091
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.055 AUD | -3.51% | -1.79% | -24.66% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.66% | 17.26M | |
+0.89% | 12.8B | |
-10.29% | 7.61B | |
+1.78% | 5.41B | |
-1.16% | 4.51B | |
+5.74% | 4.49B | |
-50.70% | 3.29B | |
+12.21% | 2.73B | |
-16.13% | 2.02B | |
-11.50% | 1.73B |
- Stock Market
- Equities
- LDX Stock
- News Lumos Diagnostics Holdings Limited
- Lumos Diagnostics Secures Two Service Agreements with Hologic